d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity
Cancer Letters · 2024
DOI: 10.1016/j.canlet.2024.216883 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Letters, 2024. Verfasst von Wenjing Dong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Ministry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical …. Hauptthemen laut MEDLINE: Programmed Cell Death 1 Receptor, Lysosomes, T-Lymphocytes, Mannose. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Fundamental Research Funds for the Central Universities, National Natural Science Foundation of China, National Key Research and Development Program of China.
Abstract (Originalsprache)
High expression of programmed cell death protein 1 (PD-1), a typical immune checkpoint, results in dysfunction of T cells in tumor microenvironment. Antibodies and inhibitors against PD-1 or its ligand (PD-L1) have been widely used in various malignant tumors. However, the mechanisms by which PD-1 is regulated are not fully understood. Here, we report a mechanism of PD-1 degradation triggered by d-mannose and the universality of this mechanism in anti-tumor immunity. We show that d-mannose inactivates GSK3β via promoting phosphorylation of GSK3β at Ser9, thereby leading to TFE3 translocation to nucleus and subsequent PD-1 proteolysis induced by enhanced lysosome biogenesis. Notably, combination of d-mannose and PD-1 blockade exhibits remarkable tumor growth suppression attributed to elevated cytotoxicity activity of T cells in vivo. Furthermore, d-mannose treatment dramatically improves the therapeutic efficacy of MEK inhibitor (MEKi) trametinib in vivo. Our findings unveil a universally unrecognized anti-tumor mechanism of d-mannose by destabilizing PD-1 and provide strategies to enhance the efficacy of both immune checkpoint blockade (ICB) and MEKi -based therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Ministry of Education Key Laboratory of Metabolism and Molecular Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Zhongshan Hospital, Fudan University, Shanghai, 200032, Chin…
- Tongji Hospital, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China.
- Dept of Medical Oncology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. Electronic address: liu.tianshu@zs-hospital.sh.cn.
- Tongji Hospital, Shanghai Key Laboratory of Signaling and Disease Research, Frontier Science Center for Stem Cell Research, School of Life Sciences and Technology, Tongji University, Shanghai, 200092, China. Electronic…
Förderung
- Fundamental Research Funds for the Central Universities
- National Natural Science Foundation of China
- National Key Research and Development Program of China
Zitieren
APA
Dong, W., Lin, M., Zhang, R., Sun, X., Li, H., Liu, T., Xu, Y., & Lv, L. (2024). d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity. Cancer Letters. https://doi.org/10.1016/j.canlet.2024.216883
Vancouver
Dong W, Lin M, Zhang R, Sun X, Li H, Liu T, et al. d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity. Cancer Letters. 2024. doi:10.1016/j.canlet.2024.216883
BibTeX
@article{Dong2024,
author = {Dong, Wenjing and Lin, Mingen and Zhang, Ruonan and Sun, Xue and Li, Hongchen and Liu, Tianshu and Xu, Yanping and Lv, Lei},
title = {d-mannose targets PD-1 to lysosomal degradation and enhances T cell-mediated anti-tumor immunity},
journal = {Cancer Letters},
year = {2024},
doi = {10.1016/j.canlet.2024.216883}
}
EUVIMED